Table 1.

Adverse Events in the 12 Patients.^*

Event	Grade 1	Grade 2	Grade 3	Total
		no.		no. (%)
Cardiac disorders
Bradycardia	2	0	0	2 (17)
Hypertension	1	0	0	1 (8)
Hypotension	1	0	0	1 (8)
Tachycardia	1	0	0	1 (8)
Ear and labyrinth disorders: external ear inflammation	0	1	0	1 (8)
Gastrointestinal disorders
Abdominal pain	1	0	0	1 (8)
Constipation	1	0	0	1 (8)
Diarrhea	3	0	0	3 (25)
Nausea	2	0	0	2 (17)
Vomiting	3	2	0	5 (42)
General disorders
Chills	1	0	0	1 (8)
Fatigue	3	0	0	3 (25)
Fever	4	0	0	4 (33)
Blood and lymphatic system: anemia	1	0	1	2 (17)
Infections and infestations: perirectal abscess	0	0	1	1 (8)
Procedural complications: postoperative hemorrhage	6	0	0	6 (50)
Investigations
Increased ALT level	0	1	1	2 (17)
Increased AST level	0	2	0	2 (17)
Decreased lymphocyte count	0	0	1	1 (8)
Decreased neutrophil count	1	0	1	2 (17)
Decreased platelet count	3	0	0	3 (25)
Weight loss	1	0	0	1 (8)
Decreased white-cell count	0	1	1	2 (17)
Metabolism and nutrition
Anorexia	2	0	0	2 (17)
Hyperphosphatemia	1	0	0	1 (8)
Obesity	0	0	1	1 (8)
Nervous system disorders
Cerebrospinal fluid leak	0	1	0	1 (8)
Dizziness	1	0	0	1 (8)
Facial nerve disorder	1	0	0	1 (8)
Headache	2	1	0	3 (25)
Peritumoral vasogenic edema	0	1	0	1 (8)
Seizure	2	0	0	2 (17)
Skin disorders: contact dermatitis	1	1	0	2 (17)
Total	45	11	7	63

^*Shown is the cumulative incidence of adverse events according to highest grade irrespective of cause within 30 days after G207 administration. There were no events of grade 4. ALT denotes alanine aminotransferase, and AST aspartate aminotransferase.